Prelude Therapeutics (PRLD) Change in Acquisitions & Divestments (2022 - 2026)

Prelude Therapeutics has disclosed Change in Acquisitions & Divestments across 5 years of filings, most recently posting $8.5 million for Q1 2026.

• Change in Acquisitions & Divestments for Q1 2026 came in at $8.5 million, down 88.15% year-over-year; the trailing twelve-month figure through Mar 2026 was $91.2 million (down 48.87% YoY), and the FY2025 annual result was $154.4 million, up 7.48% from the prior year.
• Change in Acquisitions & Divestments came in at $8.5 million for Q1 2026 at Prelude Therapeutics, up from $6.4 million in the prior quarter.
• In the past five years, Change in Acquisitions & Divestments ranged from a high of $81.4 million in Q3 2022 to a low of $6.4 million in Q4 2025.
• The 5-year median for Change in Acquisitions & Divestments is $40.1 million (2025), against an average of $41.2 million.
• Across the five-year window, Change in Acquisitions & Divestments jumped 95.01% in 2023 and sank 88.15% in 2026, its largest moves.
• Prelude Therapeutics' Change in Acquisitions & Divestments stood at $35.0 million in 2022, then surged by 95.01% to $68.2 million in 2023, then plunged by 56.78% to $29.5 million in 2024, then sank by 78.3% to $6.4 million in 2025, then jumped by 32.8% to $8.5 million in 2026.
• The last three Change in Acquisitions & Divestments figures came in at $8.5 million (Q1 2026), $6.4 million (Q4 2025), and $40.1 million (Q3 2025), per Business Quant data.